Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−50.80USD
−74.96 MUSD
15.77 MUSD
1.28 M
About Eiger BioPharmaceuticals, Inc.
Sector
CEO
David Apelian
Headquarters
Palo Alto
Website
Employees (FY)
25
Founded
2008
FIGI
BBG005DNQTV7
Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of EIGRQ is 13.10 USD — it has increased by 0.38% in the past 24 hours. Watch Eiger BioPharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Eiger BioPharmaceuticals, Inc. stocks are traded under the ticker EIGRQ.
EIGRQ stock has risen by 301.84% compared to the previous week, the month change is a 500.92% rise, over the last year Eiger BioPharmaceuticals, Inc. has showed a 98.20% decrease.
EIGRQ reached its all-time high on Mar 20, 2015 with the price of 5726341.33 USD, and its all-time low was 1.10 USD and was reached on Apr 1, 2024. View more price dynamics on EIGRQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
EIGRQ stock is 7.29% volatile and has beta coefficient of 4.41. Track Eiger BioPharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Eiger BioPharmaceuticals, Inc. there?
Today Eiger BioPharmaceuticals, Inc. has the market capitalization of 19.32 M, it has increased by 246.85% over the last week.
Yes, you can track Eiger BioPharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Eiger BioPharmaceuticals, Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
EIGRQ net income for the last quarter is −13.45 M USD, while the quarter before that showed −18.03 M USD of net income which accounts for 25.38% change. Track more Eiger BioPharmaceuticals, Inc. financial stats to get the full picture.
No, EIGRQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 27, 2024, the company has 25.00 employees. See our rating of the largest employees — is Eiger BioPharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eiger BioPharmaceuticals, Inc. EBITDA is −71.04 M USD, and current EBITDA margin is −450.36%. See more stats in Eiger BioPharmaceuticals, Inc. financial statements.
Like other stocks, EIGRQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eiger BioPharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eiger BioPharmaceuticals, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eiger BioPharmaceuticals, Inc. stock shows the sell signal. See more of Eiger BioPharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.